We’re another step closer to bringing innovative new options to people living with treatment-resistant depression. Read about new Phase 2a results from atai Life Sciences & BeckleyPsytech: ir.atai.com/news-release...

There is an urgent need for better treatment options for opioid use disorder. We're honored that atai has received this grant from the NIH, which will accelerate our ability to bring innovative new treatments to people suffering from addiction. ir.atai.com/news-release...

atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates | Atai Life Sciences N.V. Planned strategic combination with Beckley Psytech expected to solidify position as global leader in transformative, psychedelic-based mental health therapies with a short time in-clinic Reported posi...

I’m pleased to share atai’s Q2 financial results and corporate updates. This quarter has been transformational for atai. We’re proud to be a leader in developing next-gen psychedelic mental health therapies.
#MentalHealth #Biotech #Q2 #Earnings

Q4 #Earnings update: Strong financial position following a successful capital raise, with two Phase 2 trials underway & large Phase 2b results expected mid-2025. We enter 2025 in a position of strength, focused on transforming #mentalhealth. bit.ly/4ioeENc

The first patient has been dosed in Elumina, our Ph2 trial of VLS-01 for TRD – an important milestone. With ~100M people affected and limited options, we focus on conditions with high unmet need. Looking forward to the data in Q1’26. ir.atai.life/news-release...

Milestone update: Enrollment complete in Ph2b trial of Beckley Psytech’s BPL-003 for treatment-resistant depression (TRD). Results expected mid-2025. Full announcement: bit.ly/4immzun

It's so sad to read about all of the struggles that this region--where I grew up--is going through. The loss of life there is heartbreaking.

Studies show that funding from the National Institutes of Health (NIH) contributed to 354 of 356 drugs (99.4%) approved by the FDA from 2010 to 2019. Recklessly slashing NIH funding will mean that patients will be waiting much longer for life-saving treatments.

Honored to step into the role of sole CEO at atai. Thanks to @flobrand.bsky.social for his visionary leadership that brought atai to where it is today. Thrilled to build on this foundation with a strengthened leadership team. Full press release: ir.atai.life/news-release...

@drobrienmd.bsky.social

Great to see a pharmacotherapy get approved for OSA, a huge unmet medical need! This takes me back to my Cypress Bio days, where we tested a centrally acting agent in this indication in a phase 2 trial. While the trial was negative, we learned a great deal about OSA variability.

Vertex touts pain drug results, but medicine does not outperform placebo in sciatica study A Vertex drug hit its mark in a Phase 2 study in chronic pain, but faces questions about its performance versus placebo.

This is an important biotech result - and a disappointing one.

There's a desperate need for effective pain treatments that could be an alternative to opioids.

Vertex has been developing a promising one. But in a mid-stage study, it did no better than placebo.

www.statnews.com/2024/12/19/v...

(PDF) Psilocybin increases emotional empathy in patients with major depression PDF | Empathy plays a crucial role in interpersonal relationships and mental health. It is decreased in a variety of psychiatric disorders including... | Find, read and cite all the research you need ...

Psilocybin increases emotional empathy in patients with major depression
www.researchgate.net/publication/...

Congratulations to the Beckley Psytech team on the promising Phase 2a proof-of-concept results for ELE-101. The safety and efficacy signals are encouraging. We're proud to support Beckley Psytech as we continue our mission to develop scalable interventional psychiatry treatments for depression.

A Pragmatic Approach to Psychedelic Drug Development

As an engineer turned physician, I’m driven by solving complex problems - few are as urgent as developing new treatments for mental health disorders.

Listen to my convo with Brand Li here: open.spotify.com/episode/6axV...

Lando Norris via insta: "PAPAYA ON TOP"

| #F1 #McLaren

We’ve come full circle. Sickness and death - from milk specifically - in the 19th century was one of the single biggest drivers leading to the establishment of the FDA

Why inflammatory reductionism is a threat to psychiatry (and the rest of medicine) Thomas Pollak explores the emergence of a new worldview which attempts to explain all manner of ills as the result of inflammation or immune dysfunction. H

This essay has been long overdue. Chapeau to Tom Pollock for writing it.

academic.oup.com/brain/advanc...

Would love to be added! CEO at atai Life Sciences.

@daphnezohar.bsky.social, great to see you on BlueSky and to see you in person at CNS Summit!

‘We dodged a bullet’: Biotech and pharma react to selection of Marty Makary for FDA commissioner “We dodged a bullet”: Biotech and pharma react to selection of Marty Makary for FDA commissioner.

‘We dodged a bullet’: Biotech and pharma react to selection of Marty Makary for FDA commissioner
Many appear cautiously optimistic about Trump’s intended pick

www.statnews.com/2024/11/23/m...

Bluesky is the new destination for X/Twitter’s health and science community. Here's why #MedTwitter is migrating en masse from X to Bluesky, suddenly making it an essential hub for scientific discourse. Here's why.

STAT’s @katiepalmer.bsky.social documents whet feels very palpable to me: Science and med 🧬🧪twitter moving rapidly to Blue Sky social. Happy to see so many former connections here. www.statnews.com/2024/11/21/b...

Sigh

I’ve seen enough to make a call: Bluesky is going to be a legit competitor to Twitter.

Sweet.

If you're paying 100 million for Superbowl ads to convert people to Jesus instead of housing the homeless, you read the wrong book.

Boom.